Komori
Susmed (4263) · RiskFirst stated

Risks related to the adoption, competition, and regulatory changes affecting the insomnia disorder app

First written in FY2026. . Latest entry: FY2026.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Risk that original and new products fail to achieve market acceptanceA theme 29 companies write about · 29 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2024: 3 of 7 companies on the "Worse" side.

3 other companies' latest entry also says "First stated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 29 companies compared. The sentences above are computed from all 29.
Full recordFilings, disclosures and news, newest first
  1. FY2026First statedAnnual report

    「If competing products or technologies emerge or regulatory changes occur, such as revisions to reimbursement points, the speed of adoption and sales of the “サスメド insomnia disorder app Medcle®” may fall below expectations, potentially having a material impact on the company’s long-term financial position and business performance.」

    As new risks following reimbursement listing and the start of sales, the company stated that the speed of adoption and sales may fall below expectations due to the emergence of competing products or technologies or changes to the reimbursement-point system.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Susmed's next results are scheduled for 2026-11-06. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risks related to the adoption, competition, and regulatory changes affecting the insomnia disorder app | SUSMED,Inc. (4263) | Komori